Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.38 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.38 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL439716 | 0.83 | LMNA (0.59) | LMNATDP1L3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL11749881 | 0.77 | LMNA (0.37) | LMNATDP1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL11744262 | 0.77 | PDE2A (0.52) | LMNATDP1L3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL11006950 | 0.76 | ALDH1A1 (0.50) | LMNAL3MBTL1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL8595031 | 0.74 | LMNA (0.52) | LMNATDP1L3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL423189 | 0.74 | LMNA (0.52) | LMNATDP1L3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL29868033 | 0.74 | LMNA (0.52) | LMNATDP1L3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL3175016 | 0.73 | LMNA (0.55) | LMNATDP1L3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL13063222 | 0.73 | LMNA (0.50) | LMNATDP1L3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL16421175 | 0.73 | LMNA (0.50) | LMNATDP1L3MBTL1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1165524-B1 | METHOD OF PRODUCING THIOBARBITURIC ACID DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2005-06-01 | — | — | EP | disclosed |
| US-6673925-B2 | REACTING BIS(4,6-DICHLORO-2-PYRIMIDINE)DISULFIDE WITH HYDROGENOLYSIS AGENT IN THE PRESENCE OF AN INERT SOLVENT AND REACTING HYDROGENOLYSIS PRODUCT WITH ALKALI METAL METHYLATE IN METHANOL | SYNGENTA CROP PROTECTION, INC. | 2004-01-06 | — | — | US | disclosed |
| US-20020095037-A1 | Method of producing thiobarbituric acid derivatives | SYNGENTA CROP PROTECTION, INC. | 2002-07-18 | — | — | US | disclosed |
| EP-1165524-A2 | METHOD OF PRODUCING THIOBARBITURIC ACID DERIVATIVES | Syngenta Participations AG (CH) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000046212-A1 | METHOD OF PRODUCING SUBSTITUTED PYRIMIDINE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2000-08-10 | — | — | WO | disclosed |
| WO-2000046213-A2 | METHOD OF PRODUCING THIOBARBITURIC ACID DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2000-08-10 | — | — | WO | disclosed |
| US-4057634-A | Antiprotozoal(1-alkyl-5-nitro-imidazolyl-2-alkyl)-pyridazines | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-11-08 | — | — | US | disclosed |
| US-3991191-A | Antiprotozoal (1-alkyl-5-nitro-imidazolyl-2-alkyl)-pyrimidines | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020095037-A1 | Method of producing thiobarbituric acid derivatives | BHMT2, MGMT, MRM1 | LMNA 4402/4885TDP1 2097/4885L3MBTL1 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.